Frontiers in Pharmacology has retracted a 2020 study on the oleander-derived drug PBI-05204 for glioblastoma after image integrity concerns and missing raw data.
The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...
Forbes contributors publish independent expert analyses and insights. Mary Crossan is a professor and global expert in strategic leadership This voice experience is generated by AI. Learn more. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results